Bicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $13,559,062.72 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker bought 985,397 shares of the stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, December 16th, Bros. Advisors Lp Baker acquired 500,000 shares of Bicycle Therapeutics stock. The stock was bought at an average price of $15.34 per share, with a total value of $7,670,000.00.

Bicycle Therapeutics Stock Performance

Shares of BCYC traded up $0.02 during mid-day trading on Tuesday, reaching $15.14. The stock had a trading volume of 2,234,373 shares, compared to its average volume of 403,121. The business has a fifty day moving average of $22.62 and a 200 day moving average of $22.71. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -4.60 and a beta of 0.86. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm's revenue was down 50.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.26) EPS. On average, research analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors have recently bought and sold shares of BCYC. Point72 Asset Management L.P. raised its holdings in shares of Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock worth $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Avoro Capital Advisors LLC bought a new position in Bicycle Therapeutics during the second quarter valued at $14,168,000. Perceptive Advisors LLC bought a new position in Bicycle Therapeutics during the second quarter valued at $11,577,000. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics in the third quarter worth about $10,028,000. Finally, Westfield Capital Management Co. LP increased its position in shares of Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock valued at $41,887,000 after purchasing an additional 327,089 shares during the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright decreased their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating on the stock in a research note on Monday. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Needham & Company LLC reissued a "buy" rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald restated an "overweight" rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $36.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.